ReviewHuman vaccines & immunotherapeutics2018
The global fight to develop antipoverty vaccines in the anti-vaccine era.
Review in Human vaccines & immunotherapeutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 36 citations in OpenAlex.
- The quest for more effective vaccine markets - Opportunities, challenges, and what has changed with the SARS-CoV-2 pandemic.Vaccine · 2024Review
- Analyzing the Evolution and Host Adaptation of the Rabies Virus from the Perspective of Codon Usage Bias.Transboundary and emerging diseases · 2023Article
- Translating diagnostics and drug delivery technologies to low-resource settings.Science translational medicine · 2022Review
- Nanovaccines against Animal Pathogens: The Latest Findings.Vaccines · 2021Review
- Human leishmaniasis vaccines: Use cases, target population and potential global demand.PLoS neglected tropical diseases · 2021Article
- Soil-Transmitted Helminth Vaccines: Are We Getting Closer?Frontiers in immunology · 2020Review
- Review
- DR Congo and Nigeria: New neglected tropical disease threats and solutions for the bottom 40.PLoS neglected tropical diseases · 2019Article
- Science tikkun: A framework embracing the right of access to innovation and translational medicine on a global scale.PLoS neglected tropical diseases · 2019Article
- Pediatric tropical medicine: The neglected diseases of children.PLoS neglected tropical diseases · 2019Article
- Strategies to increase adoption of animal vaccines by smallholder farmers with focus on neglected diseases and marginalized populations.PLoS neglected tropical diseases · 2019Review
- WIPO Re:Search-A Platform for Product-Centered Cross-Sector Partnerships for the Elimination of Schistosomiasis.Tropical medicine and infectious disease · 2019Article
- "Running the Gauntlet": Formidable challenges in advancing neglected tropical diseases vaccines from development through licensure, and a "Call to Action".Human vaccines & immunotherapeutics · 2019Review
- IL-4 Mediated Resistance of BALB/c Mice to Visceral Leishmaniasis Is Independent of IL-4Rα Signaling via T Cells.Frontiers in immunology · 2019Article
- Recent Vaccines against Emerging and Tropical Infectious Diseases.Discoveries (Craiova, Romania)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antipoverty vaccines are the vaccines targeting a group of approximately 20 neglected tropical diseases (NTDs), as currently defined by the World Health Organization (WHO). The "antipoverty" moniker refers to the fact that NTDs trap populations in poverty due to their chronic and deleterious effects on child intellect and worker productivity. Therefore, NTD vaccines can be expected to promote both global health and economic advancement. Unfortunately, antipoverty vaccine development has lagged behind vaccines for major childhood infections and pandemic threats, despite evidence for their cost-effectiveness and cost-savings. Currently, the only licensed vaccines for NTDs include those for yellow fever, dengue, and rabies, although several other NTD vaccines for hookworm disease, schistosomiasis, leishmaniasis, and Zika and Ebola virus infections are in different stages of clinical development, while others are at the preclinical development stage. With the exception of the viral NTD vaccines there so far has been minimal industry interest in the antipoverty vaccines, leaving their development to a handful of non-profit product development partnerships. The major scientific and geopolitical hurdles to antipoverty vaccine development are discussed, including a rising antivaccine ("antivax") movement now entering highly populated low- and middle-income countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.